• Publications
  • Influence
A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b
TLDR
The large-scale synthesis, pharmaceutical development, and clinical evaluation of a conjugate vaccine composed of a synthetic capsular polysaccharide antigen of Haemophilus influenzae type b (Hib) demonstrate that access to synthetic complex carbohydrate–based vaccines is feasible and provides a basis for further development of similar approaches for other human pathogens.
T-Cell Immunity of Carbohydrates
TLDR
In this review, different types of T-cell activation processes and possible involvements of carbohydrate antigens will be discussed.
Phase I Clinical Evaluation of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b in Human Adult Volunteers
TLDR
The first two phase I clinical trials conducted with human adult volunteers under double blind, randomized conditions found an excellent safety profile and an antibody response similar to the one observed for the control vaccine.
Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b
TLDR
The antigenicity and immunogenicity of several H. influenzae type b synthetic oligosaccharide-protein conjugates in laboratory animals are described and these synthetic versions induced similar antibody response patterns in terms of titer, specificity, and functional capacity.
Glycosides of Monoallyl Diethylene Glycol. A New Type of Spacer Group for Synthetic Oligosaccharides
Abstract The preparation of spacer-armed synthetic oligosaccharides, which can be coupled to either proteins or polymers for use respectively as immunogens or immunoadsorbants for affinity
Conjugation of 5-azido-3-oxapentyl glycosides with thiolated proteins through the use of thiophilic derivatives
TLDR
5-Azido-3-oxa-pentyl beta-D-galactopyranoside was prepared from diethylene glycol monochlorohydrin and used as a model of oligosaccharide hapten demonstrating the usefulness of the methodology.
Haemophilus influenzae Type b Conjugate Vaccine with a Synthetic Capsular Polysaccharide Antigen : Chemical View
TLDR
The technology for using a synthetic antigen in a commercial vaccine remains a formidable challenge and major chemical problems to be solved and the strategies employed to produce the first vaccine containing a synthetic carbohydrate antigen that becomes commercially available are described.
...
1
2
...